

CURRICULUM VITAE

PERSONAL



NAME(姓名，含英譯)

歐凰姿 Huang-tz Ou

PROFESSIONAL APPOINTMENT (現職，含英譯)

成功大學藥學系暨臨床藥學研究所 教授

National Cheng Kung University, School of Pharmacy & Institute of Clinical Pharmacy and Pharmaceutical Sciences, Professor

EDUCATION(學歷)

- 美國密西根大學 藥事行政管理(University of Michigan, Ann Arbor, MI, USA), 博士 (2006/9 - 2010/5)
- 成功大學 臨床藥學研究, 碩士(2003/9 – 2005/6)
- 中國醫藥大學 學士(1999/9 - 2003/6)

WORKING EXPERIENCE (經歷)

MAJOR RESEARCH AREA(研究領域)

- 成功大學藥學系暨臨床藥學研究所 副教授 (2017/2-2021/7)
- 成功大學藥學系暨臨床藥學研究所 助理教授 (2012/8-2017/1)
- 美國南達克達大學 助理教授 (2011/8-2012/7)
- 美國密西根大學 博士後研究員 (2010/8-2011/7)
- 美國密西根大學 研究助理 (2006/8-2010/7)

PUBLICATION(In the nearest 5 years)(發表、出版物)

(2018~2023)

1. Chun-Ting Yang, Wen-Yu Yao, Chen-Yi Yang, **Huang-Tz Ou**, Shihchen Kuo. Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework. *Journal of Internal Medicine* 2024, 295.3: 357-368. **(corresponding author)** [Medicine, General & Internal, IF: 11.10, avg5_IF:10.50, Rank: 18/168]
2. Hsuan-Yu Su, Chen-Yi Yang, Yi-Hsin Chang, Shyi-Gen Chen, Jui-Ching Chen, Hui-Ju Ho, **Huang-Tz Ou**, Shihchen Kuo. Cost-Effectiveness of Novel Macrophage-Regulating Treatment on Wound Healing in Patients with Diabetic Foot Ulcers. *JAMA network open*, 2023, 6.1: e2250639-e2250639. **(corresponding author)** [MEDICINE, GENERAL & INTERNAL, IF: 13.8, avg5_IF: 13.0, Rank: 15/169]
3. Zi-Yang Peng, Chun-Ting Yang, Wei-Hung Lin, Wen-Yu Yao, **Huang-Tz Ou**, Shihchen Kuo. Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: A nationwide cohort study. *Cardiovascular Diabetology*, 2023, 22.1: 272. **(corresponding author)** [Endocrinology & Metabolism, IF: 9.3, avg5_IF:9.6, Rank: 10/145]
4. Zi-Yang Peng, Yao-Tseng Wang, Chin-Sung Chang, Chih-Hsing Wu, **Huang-Tz Ou**. Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study. *Diabetes & Metabolism* 2023, 49.5: 101465. **(corresponding author)** [Endocrinology & Metabolism, IF: 7.200, avg5_IF:5.800, Rank: 22/145]
5. Szu-Chun Yang, **Huang-Tz Ou**, Wu-Chou Su, Shi-Yi Wang. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer. *Cancer Medicine* 2023 Jan 18. doi: 10.1002/cam4.5632. (2nd author) [Oncology, IF: 4.0, avg5_IF:4.5, Rank: 96/241]
6. Wei-Pang Chung, Chun-Ting Yang, Shuen-Ru Yang, Ching-Yen Su, Hsin-Wei Su, Shang-Yun Liu, **Huang-Tz Ou**. Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - Role of trastuzumab in HER2+ BC and platinum in TNBC. *Frontiers in Oncology* 2023 Jan

- 24;12:1022994. doi: 10.3389/fonc.2022.1022994. **(corresponding author)** [Oncology, IF: 4.7, avg5_IF:5.2, Rank: 85/241]
7. Chih-Wei Lin, Meng-Hsing Wu, Yu-Lin Mau, Pei-Fang Su, and **Huang-Tz Ou**. Effect of atosiban on in vitro fertilization pregnancy outcome among women with endometriosis in presence or absence of adenomyosis. *Taiwanese Journal of Obstetrics and Gynecology* 2023, 62.4: 537-542. **(corresponding author)** [Obstetrics & Gynecology, IF: 2.1, avg5_IF:2.0, Rank: 57/85]
 8. Hsuan-Yu Su, Chen-Yi Yang, **Huang-Tz Ou**, Shyi-Gen Chen, MD, Jui-Ching Chen, Hui-Ju Ho, Shihchen Kuo. Cost-effectiveness of novel macrophage-regulating treatment on wound healing in patients with diabetic foot ulcers. *JAMA Network Open* 2023 Jan 3;6(1):e2250639. doi: 10.1001/jamanetworkopen.2022.50639. **(co-corresponding author)** [Medicine, general & internal, IF: 13.8, avg5_IF: 13.0, Rank: 15/169]
 9. Zi-Yang Peng, Chun-Ting Yang, Shihchen Kuo, Chih-Hsing Wu, Wei-Hung Lin, **Huang-Tz Ou**. Restricted mean survival time analysis for SGLT2i-associated real-world heterogeneous treatment effects on primary and secondary prevention of cardiorenal outcomes *JAMA Network Open* 2022;5(12):e2246928. doi:10.1001/jamanetworkopen.2022.46928 **(corresponding author)** [Medicine, general & internal, IF: 13.8, avg5_IF: 13.0, Rank: 15/169]
 10. Hsin-Ta Lin, Meng-Hsing Wu, Li-Chung Tsai, Ta-Sheng Chen, Chao-Chin Hsu, and **Huang-Tz Ou**. Incorporating sperm DNA fragmentation index with computer-assisted semen morphokinematic parameters as a better window to male fertility. *Chinese Journal of Physiology* 2022 May-Jun;65(3):143-150. doi: 10.4103/CJP.CJP_12_22. PMID: 35775533. **(co-corresponding author)** [Physiology, IF: 1.8, avg5_IF:1.7, Rank: 64/79]
 11. Yu-Hsuan Hsu, Chia-Chun Li, Fu-Wen Liang, Zi-Yang Peng, Yin-Fan Chang, Jason C. Hsu, **Huang-Tz Ou**, and Chih-Hsing Wu. Reduced all-cause mortality with bisphosphonates among post-fracture osteoporosis patients: a nationwide study and systematic review *Clinical Pharmacology & Therapeutics* 2022 Sep;112(3):711-719. doi: 10.1002/cpt.2645. Epub 2022 Jun 4. PMID: 35561128. **(co-corresponding author)** [Pharmacology & Pharmacy, IF: 6.7, avg5_IF:6.6, Rank: 28/278]
 12. Pei-Fang Su, Junjiang Zhong, Yi-Chia Liu, Tzu-Hsuan Lin, **Huang-tz Ou**. Efficient estimation of a Cox model when integrating the subgroup incidence rate information. *Journal of Applied Statistics*. 2022: 1-20 [Statistics & probability, IF: 1.5, avg5_IF:1.4, Rank: 58/125]
 13. Chien Ning Hsu, Kelly Huang, Fang Ju Lin, **Huang Tz Ou**, Ling Ya Huang, Hsiao Ching Kuo, Chi Chuan Wang, Sengwee Toh. Continuity and completeness of electronic health

- record data for patients treated with oral hypoglycemic agents: findings from healthcare delivery systems in Taiwan. *Frontiers in Pharmacology* 2022 Apr 4;13:845949. doi: 10.3389/fphar.2022.845949. [Pharmacy and Pharmacology, IF: 5.6, avg5_IF:6.1, Rank: 44/278]
14. Zi-Yang Peng, Chun-Ting Yang, **Huang-Tz Ou**, Shihchen Kuo. Cost-effectiveness of SGLT2is versus DPP4is among type 2 diabetes patients with and without established cardiovascular disease: A model-based simulation analysis using 10-year real-world data and targeted literature review. *Diabetes Obesity & Metabolism* 2022 July 24(7):1328-1337. doi: 10.1111/dom.14708. (**corresponding author**) [Endocrinology & Metabolism, IF: 5.8, avg5_IF:5.6, Rank: 31/145]
 15. Chun-Ting Yang, Zi-Yang Peng, Yi-Chi Chen, **Huang-Tz Ou**, Shihchen Kuo. Cardiovascular benefits with favorable renal, amputation and hypoglycemic outcomes of SGLT-2 inhibitors in type 2 diabetes from the Asian perspective: A population-based cohort study and systematic review. *Frontiers in Endocrinology* 2022 March 7(13):836365. doi: 10.3389/fendo.2022.836365. (**corresponding author**) [Endocrinology & Metabolism, IF: 5.2, avg5_IF:5.9, Rank: 36/145]
 16. Hsin-Ta Lin, Meng-Hsing Wu, Li-Chung Tsai, Ta-Sheng Chen, and **Huang-Tz Ou**. Co-administration of clomiphene citrate and letrozole in mild ovarian stimulation versus conventional controlled ovarian stimulation among POSEIDON Group 4 patients. *Frontiers in Endocrinology* 2022 Jan 14;12:780392. doi: 10.3389/fendo.2021.780392. (**corresponding author**) [Endocrinology & Metabolism, IF: 5.2, avg5_IF:5.9, Rank: 36/145]
 17. Chen-Yi Yang, Shihchen Kuo, Edward Chia-Cheng Lai, **Huang-Tz Ou**. Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies *Scientific Reports* 2022 Jan 7;12(1):214. doi: 10.1038/s41598-021-04014-z. (**corresponding author**) [Multidisciplinary sciences, IF: 4.6, avg5_IF:4.9, Rank: 22/73]
 18. Chia-Te Liao, Chun-Ting Yang, Hsiu Kuo, Mei-Chuan Lee, Wei-Ting Chang, Hsin-Ju Tang, Yi-Ming Hua, Hung-Yu Chang, Zhih-cherng Chen, Carol Strong, **Huang-tz Ou**, Han-Siong Toh. Cost-effectiveness evaluation of add-on empagliflozin in patients with heart failure and a reduced ejection fraction from the healthcare system's perspective in the Asia-Pacific region. *Frontiers in Cardiovascular Medicine* doi.org/10.3389/fcvm.2021.750381 2021 Oct 29;8:750381. doi: 10.3389/fcvm.2021.750381. [Cardiac & Cardiovascular system, IF: 3.6, avg5_IF:4.1, Rank: 61/143]

19. Fang-Ju Lin, Chi-Chuan Wang, Chien-Ning Hsu, Chen-Yi Yang, Chih-Yuan Wang, **Huang-Tz Ou**. Renoprotective Effect of SGLT-2 Inhibitors among Type 2 Diabetes Patients with Different Baseline Kidney Function: A Multi-Center Study. *Cardiovascular Diabetology* doi.org/10.1186/s12933-021-01396-2 2021 Oct 7;20(1):203. doi: 10.1186/s12933-021-01396-2. (**corresponding author**) [Endocrinology & Metabolism, IF: 9.3, avg5_IF:9.6, Rank: 10/145]
20. Ben Johnson, Edward Chia-Cheng Lai, **Huang-tz Ou**, Hong Li, Björn Stollenwerk. Real-World Cost Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Taiwan. *Archives of Osteoporosis* doi:10.1007/s11657-021-01020-6 2021 Oct 12;16(1):155. doi: 10.1007/s11657-021-01020-6. (3rd author) [Orthopedics, IF: 3.0, avg5_IF:3.0, Rank: 22/86]
21. Chia-Te Liao, Chun-Ting Yang, Han Siong Toh, Wei-Ting Chang, Hung-Yu Chang, Fang-Hsiu Kuo, Mei-Chuan Lee, Yi-Ming Hua, Hsin-Ju Tang, Carol Strong, **Huang-Tz Ou**. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region. *Cardiovascular Diabetology* 2021;October 9:20(1):204. (**corresponding author**) [Endocrinology & Metabolism, IF: 9.3, avg5_IF:9.6, Rank: 10/145]
22. Hsuan-Ying Chen, Chen-Yi Yang, Cheng-Yang Hsieh, Chun-Yin Yeh, Chang-Chun Chen, Yen-Chin Chen, Chung-Chih Lai, Rebecca Claire Harris, **Huang-Tz Ou**, Nai-Ying Ko, Wen-Chien Ko. Long-term neurological and healthcare burden of Japanese Encephalitis-infected adults: a nationwide cohort study followed for 15 years. *PLOS Neglected Tropical Diseases* doi.org/10.1371/journal.pntd.0009703 2021 Sep 14;15(9):e0009703. doi: 10.1371/journal.pntd.0009703. (**corresponding author**) [Tropical medicine, IF: 3.8, avg5_IF:4.1, Rank: 2/24]
23. Shihchen Kuo, Chun-Ting Yang, Hsuan-Ying Chen, **Huang-Tz Ou**. Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases. *Journal of Diabetes Investigation* 2021 Sep;12(9):1749-1758. (**corresponding author**) [Endocrinology & Metabolism, IF: 3.2, avg5_IF:3.7, Rank: 89/145]
24. Chun-Ting Yang, Wei-Hung Lin, MD, Lun-Jie Li, **Huang-Tz Ou**, Shihchen Kuo. Association of renal and cardiovascular safety with DPP-4 inhibitors vs sulfonylureas in type 2 diabetes patients with advanced chronic kidney disease. *Clinical Pharmacology & Therapeutics* 2021 August;110(2):464-472. doi: 10.1002/cpt.2262. (**corresponding author**) [Pharmacology & Pharmacy, IF: 6.7, avg5_IF:6.6, Rank: 28/278]
25. Wei-Pang Chung, Chun-Ting Yang, Hsuan-Ying Chen, Ching-Yen Su, Hsin-Wei Su, **Huang-Tz Ou**. Treatment-associated survival outcomes in real-world patients with de

- novo metastatic triple-negative breast cancer: age as a significant treatment effect-modifier. *Journal of the Formosan Medical Association* 2021 May 15;S0929-6646(21)00185-6. doi: 10.1016/j.jfma.2021.04.028. **(corresponding author)** [Medicine, General & Internal, IF: 3.2, avg5_IF:3.3, Rank: 72/169]
26. Sarah-Jane Anderson, Chiung-Yuan Hsu, **Huang-Tz Ou**, Nai-Ying Ko, Chun-Ting Yang, Sara Lopes. Cost-effectiveness of Juluca for human immunodeficiency virus infection treatment in virologically suppressed adults in Taiwan. *Value in Health Regional Issues* 2021 May 1; 24:216-233. (third author) [Health Policy & Services, IF:2.0]
 27. Chun-Ting Yang, Kuan-Ying Li, Chen-Yi Yang, **Huang-Tz Ou**, Shihchen Kuo. A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes. *Scientific Reports* 2021 February 18;11(1):4152. **(corresponding author)** [Multidisciplinary sciences, IF: 4.6, avg5_IF:4.9, Rank: 22/73]
 28. Chen-Yi Yang, Ying-Ren Chen, **Huang-Tz Ou**, Shihchen Kuo. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. *Cardiovascular Diabetology* 2021 January 19;20(1):21. **(corresponding author)** [Endocrinology & Metabolism, IF: 9.3, avg5_IF:9.6, Rank: 10/145]
 29. Kelly Huang, Fang-Ju Lin, **Huang-Tz Ou**, Chien-Ning Hsu, Ling-Ya Huang, Chi-Chuan Wang*, Sengwee Toh. Building an Active Medical Product Safety Surveillance System in Taiwan: Adaptation of the U.S. Sentinel System Common Data Model Structure to the National Health Insurance Research Database in Taiwan. *Pharmacoepidemiology and Drug Safety* 2021 January;30:97-101. (3rd author) [Public, Environment & Occupational Health, IF: 2.6, avg5_IF:3.0, Rank: 128/207]
 30. Meng-Hsing Wu, Kah Suan Chong, New Geok Huey, **Huang-Tz Ou**, Chung-Ying Lin. Quality of life with pregnancy outcomes: Further evaluating item properties for refined Taiwan's FertiQoL. *Journal of the Formosan Medical Association* 2021 March;120(3):939-946. **(corresponding author)** [Medicine, General & Internal, IF: 3.2, avg5_IF:3.3, Rank: 72/169]
 31. Chen-Yi Yang, Wei-Ann Lin, Pei-Fang Su, Lun-Jie Li, Chun-Ting Yang, **Huang-Tz Ou**, Shihchen Kuo. Heterogeneous treatment effects on cardiovascular diseases with dipeptidyl peptidase-4 inhibitors versus sulfonylureas in type 2 diabetes patients. *Clinical Pharmacology & Therapeutics* 2021 March;109(3):772-781. **(corresponding author)** [Pharmacology & Pharmacy, IF: 6.7, avg5_IF:6.6, Rank: 28/278]

32. Shihchen Kuo, **Huang-tz Ou**, Jason Wang. Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future. *Journal of the American Pharmacists Association* 2021 January–February;61(1):e12-e15. (2nd author) [Pharmacology & Pharmacy, IF: 2.1, avg5_IF:2.2, Rank: 212/278]
33. Pei-Fang Su, Fei-Ci Sie, Chun-Ting Yang, Yu-Lin Mau, Shihchen Kuo, **Huang-Tz Ou**. Association of ambient air pollution with cardiovascular disease risks in people with type 2 diabetes: a Bayesian spatial survival analysis. *Environmental Health* 2020 December;19(1):1-12. (**corresponding author**) [Public, Environment & Occupational Health, IF: 6.0, avg5_IF:7.0, Rank: 32/207]
34. Kai-Cheng Chang, Shih-Chieh Shao, Shihchen Kuo, Chen-Yi Yang, Hui-Yu Chen, Yuk-Ying Chan, **Huang-Tz Ou**. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. *Cardiovascular Diabetology*. 2020 October;19(1):172. (**corresponding author**) [Endocrinology & Metabolism, IF: 9.3, avg5_IF:9.6, Rank: 10/145]
35. Wei-Hung Lin, Chen-Yi Yang, Shihchen Kuo, Te-Hui Kuo, Jun-Neng Roan, Chung-Yi Li, Ming-Cheng Wang, **Huang-Tz Ou**. Hepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal study. *Diabetes Research and Clinical Practice* 2020 October 6;108489. (**corresponding author**) [Endocrinology & Metabolism, IF: 5.1, avg5_IF: 6.1, Rank: 37/145]
36. Chen-Yi Yang, Pei-Fang Su, Jo-Ying Hung, **Huang-Tz Ou**, Shihchen Kuo. Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes. *Cardiovascular Diabetology* 2020 July;19(1):105. (**corresponding author**) [Endocrinology & Metabolism, IF: 9.3, avg5_IF:9.6, Rank: 10/145]
37. Tsung-Ying Lee, Hsuan-Ying Chen, Tsai-Yun Chen, Sin-Syue Li, Wei-Tse Fang, Yao-Chun Wen, Yu-Wen Lo, **Huang-Tz Ou**. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B-cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system. *European Journal of Health Economics* 2020 September;21(7):1105-1116. (**corresponding author**) [Health policy & Services, IF: 4.4, avg5_IF:4.0, Rank: 12/87]
38. Hsuan-Ying Chen, Shihchen Kuo, Pei-Fang Su, Jin-Shang Wu, **Huang-Tz Ou**. Healthcare costs associated with macrovascular, microvascular, and metabolic complications of type 2 diabetes across time: Estimates from a population-based cohort of over 0.8 million individuals with up to 15 years of follow-up. *Diabetes Care* 2020 August;43(8):1732-1740.

(corresponding author) [Endocrinology & Metabolism, IF: 16.2, avg5_IF:16.0, Rank: 6/145]

39. **Huang-Tz Ou**, and Yea-Huei Kao Yang. Community Pharmacists in Taiwan at the Frontline Against the Novel Coronavirus Pandemic: Gatekeepers for the Rationing of Personal Protective Equipment. *Annals of Internal Medicine* 2020 July;173(2):149-150. **(1st author)** [Medicine, general & internal, IF: 39.2, avg5_IF:35.3, Rank: 6/172]
40. Chun-Ting Yang, Chen-Yi Yang, **Huang-Tz Ou**, Shihchen Kuo. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. *Cardiovascular Diabetology* 2020 June;19(1):83. **(corresponding author)** [Endocrinology & Metabolism, IF: 9.3, avg5_IF:9.6, Rank: 10/145]
41. Meng-Hsing Wu, Pei-Fang Su, Wei-Ying Chu, Chih-Wei Lin, New Geok Huey, Chung-Ying Lin, **Huang-Tz Ou**. Quality of life among infertile women with endometriosis undergoing IVF treatment and their pregnancy outcomes. *Journal of Psychosomatic Obstetrics & Gynecology* 2021 March;42(1):57-66. **(corresponding author)** [Obstetrics & Gynecology, IF: 3.1, avg5_IF:3.2, Rank: 32/85]
42. Chia-Te Liao, Chun-Ting Yang, Pin-Hao Chen, Han Siong Toh, Shihchen Kuo, Zhih-Cherng Chen, **Huang-Tz Ou**, Nai-Ying Ko, Jung-Der Wang. Association of adherence to antiretroviral therapy with economic burden of cardiovascular disease in HIV-infected population. *European Journal of Preventive Cardiology* 2020 March 2;2047487320908085. doi: 10.1177/2047487320908085. **(corresponding author)** [Cardiac & cardiovascular systems, IF: 8.3, avg5_IF:7.1, Rank: 21/143]
43. Chun-Ting Yang, Han-Siong Toh, Chia-Te Liao, Shihchen Kuo, **Huang-Tz Ou**, Nai-Ying Ko. Early scale-up of antiretroviral therapy at diagnosis for reducing economic burden of cardiometabolic disease in HIV-infected population. *AIDS* 2020 May;34(6):903-911. **(corresponding author)** [Infectious Disease, IF: 3.8, avg5_IF:4.0, Rank: 49/96]
44. Tsung-Ying Lee, Shihchen Kuo, Chen-Yi Yang, **Huang-Tz Ou**. Cost-effectiveness of long-acting insulin analogues versus intermediate/long-acting human insulin for type 1 diabetes: a population-based cohort following over 10 years. *British Journal of Clinical Pharmacology* 2020 May;86(5):852-860. **(corresponding author)** [Pharmacology & Pharmacy, IF: 3.4, avg5_IF:3.8, Rank: 125/278]
45. Han-Siong Toh, Chun-Ting Yang, Kai-Li Yang, Han-Chang Ku, Chia-Te Liao, Shihchen Kuo, Hung-Jen Tang, Wen-Chien Ko, **Huang-Tz Ou**, Nai-Ying Ko. Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy.

- International Journal of Infectious Diseases 2020 February;91;44-49. (**corresponding author**) [Infectious diseases, IF: 8.4, avg5_IF:6.7, Rank: 13/96]
46. Meng-Hsing Wu, Chih-Wei Lin, Pei-Fang Su, Edward Chai-Cheng Lai, Fei-Ci Sie, Yu-Lin Mau, New Geok Huey, **Huang-Tz Ou**. Atosiban and pregnancy outcomes following in vitro fertilization treatment for infertile women requiring one, two or more embryo transfer cycles: a longitudinal cohort study. Reproductive Sciences 2020 March;27;853-859. (**corresponding author**) [OBSTETRICS & GYNECOLOGY, IF: 2.9, avg5_IF:2.9, Rank: 36/85]
47. Meng-Hsing Wu, Pei-Fang Su, Wei-Ying Chu, New Geok Huey, Chih-Wei Lin, **Huang-Tz Ou** and Chung-Ying Lin. Quality of life and pregnancy outcomes among women undergoing in vitro fertilization treatment: A longitudinal cohort study. Journal of the Formosan Medical Association 2020 July;119;471-479. (**corresponding author**) [Medicine, General & Internal, IF: 3.2, avg5_IF:3.3, Rank: 72/169]
48. **Huang-Tz Ou**, Wei-Pang Chung, Pei-Fang Su, Tzu-Hsuan Lin, Ji-Ying Lin, Yao-Chun Wen, Wei-Tse Fang. Health related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan. European Journal of Cancer Care 2019 July;28(4): e13069. (**1st and corresponding author**) [Nursing, IF: 2.1, avg5_IF:2.8, Rank: 56/125]
49. Shihchen Kuo, Chun-Ting Yang, Jin-Shang Wu, **Huang-Tz Ou**. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study. Diabetes Obesity & Metabolism 2019 February; 21:312–320. (**corresponding author**) [Endocrinology & Metabolism, IF: 5.8, avg5_IF:5.6, Rank: 31/145]
50. Pei-Fang Su, Junjiang Zhong, **Huang-Tz Ou**. Semiparametric additive rates model for recurrent events data with intermittent gaps. Statistics in Medicine 2018 November;1–14. (3rd author) [MATHEMATICAL & COMPUTATIONAL BIOLOGY, IF: 2.0, avg5_IF:2.7, Rank: 34/55]
51. Chung-Ying Lin, **Huang-tz Ou**, Mehdi Nikoobakht, Anders Broström, Kristofer Årestedt, Amir H Pakpour. Validation of the 5-Item Medication Adherence Report Scale in Older Stroke Patients in Iran. Journal of Cardiovascular Nursing 2018 November;33(6):536-543. (2nd author) [Nursing, IF: 2.0, avg5_IF:2.5 Rank: 56/123]
52. Wen-Hsuan Hou, Kai-Cheng Chang, Chung-Yi Li, **Huang-tz Ou**. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study. British Journal of Clinical Pharmacology 2018

- September;84(9): 2029-2039. (**corresponding author**) [Pharmacology & Pharmacy, IF: 3.4, avg5_IF:3.8, Rank: 125/278]
53. Meng-Hsing Wu, Pei-Fang Su, Kuan-Ya Chen, Tung-Hee Tie, Hsu-Cheng Ke, Hau Chen, Yu-Chi Su, Yu-Chen Su, **Huang-Tz Ou**. Heart rate variability among women undergoing in vitro fertilization treatment: Its predictive ability for pregnancy. PLoS One 2018 March 12;13(3):e0193899. (**corresponding author**) [Multidisciplinary sciences, IF: 3.7, avg5_IF:3.8, Rank: 26/73]
54. Chieh-Hsiang Lu, Chen-Yi Yang, Chung-Yi Li, Cheng-Yang Hsieh, **Huang-Tz Ou**. Lower risk of dementia associated with use of pioglitazone as compared to other second-line treatments to metformin-based dual therapy: a population-based longitudinal study for the period 2000-2013 in Taiwan. Diabetologia 2018 March; 61(3):562-573. (**corresponding author**) [Endocrinology & Metabolism, IF: 8.2, avg5_IF:9.7, Rank: 13/145]
55. **Huang-Tz Ou**, Tsung-Ying Lee, Ye-Fong Du, Chung-Yi Li. Comparative risks of diabetes-related complications of basal insulins: a longitudinal population-based cohort of type 1 diabetes 1999-2013 in Taiwan. British Journal of Clinical Pharmacology 2018 February;84(2):379-391. (**1st author & corresponding author**) [Pharmacology & Pharmacy, IF: 3.4, avg5_IF:3.8, Rank: 125/278]

本頁為範例(完稿繳交時，可刪除本頁)

講題中、英文、以一頁 A4 為限，至少 300 字

糖尿病患者的慢性疾病治療，以複方藥物的使用是具有成本效益的嗎？(以藥事經濟學的觀點)

Cost-effectiveness of Upfront Combination Therapy for Chronic Disease Medication in Patients with Diabetic (from the Taiwan Health Care Sector Perspective)

歐鳳姿

成功大學藥學系教授

中文摘要

藥物研發是台灣目前正積極發展的產業類別，也是一個與我們健康息息相關的議題。以藥物上市生命週期來看，在準備上市時，我們大多直接由大型臨床試驗推論新型藥品相較現有治療是否有更好的療效或安全；這是所謂的醫療科技評估(health technology assessment)來支持新醫療科技(含藥品)是否值得上市。上市後，考量真實世界病患異質性，且台灣藥品健保的給付限縮，我們需要更進一步的檢視藥物上市後是否真正的有效益？對哪類病患是更加有效(或有是害)？是否帶來額外價值(如，除了延長我們的生命也能提升生活品質)？所以值得我們繼續去支付這些藥品；這是所謂醫療科技再評估(health technology re-assessment)精神，藉由真實世界使用經驗產生證據以支持醫療科技的合理使用與優化醫療資源分配。

演講中將以藥事經濟學的觀點探討近期三高相關的複方藥物，以成本效益、或其他醫療科技評估的方法，來看這些新複方新藥的是否值得臨床更廣泛的應用。

Abstract:

Drug development is currently a thriving industry in Taiwan, closely intertwined with our health. In a drug's life cycle, its efficacy and safety evidence through large-scale, head-to-head, and randomized phase III clinical trials is typically applied in support of its launch into a market. This is so-called "health technology assessment", which is based on promising trial data to support the decision-making of adopting new technologies (including drugs) in a market. Following the launch in a market, given real-world populations comprising diverse clinical characteristics and strict reimbursement environment of Taiwan's pharmaceutical healthcare system, we should further scrutinize whether these drugs provide genuine benefits post-market approval, thereby adding more value (e.g., improving quality of life in addition to extending our lifespan), justifying the cost of these medications. This is so-called "health technology re-assessment", which is rooted in real-world evidence to facilitate the rational use of new technologies and optimize the allocation of health care resource.

This presentation will approach the recent combination therapies for chronic disease from the perspective of pharmacoeconomics. Through cost-effectiveness analyses or other relevant methodologies regarding health technology assessment, we will examine whether these new combination drugs for conditions like hyperlipidemia, hypertension, and diabetes warrant broader clinical applications.